A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea

NCT01274897 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: Novartis MenACWY-CRM
BIOLOGICAL: Saline Placebo

Sponsor

Novartis Vaccines